Eugene Krustev Headshot

Dr. Eugene Krustev

MD, MSc, FRCPC
Pronouns: he/him

Affiliations

Full Member

McCaig Institute for Bone and Joint Health

Contact information

Preferred method of communication

I am currently seeking graduate students to join my research program starting in Summer 2026. I also welcome research collaborations and trainees interested in autoimmune muscle diseases, biomarker discovery, and translational immunology—opportunities are available to begin immediately. Please feel free to email with any inquiries. 

Background

Educational Background

Bachelor of Science Neuroscience, Dalhousie University, 2013

Master of Science Pharmacology, Dalhousie University, 2015

Doctor of Medicine Memorial University of Newfoundland, 2019

Internal Medicine Residency University of Calgary, 2022

Rheumatology Residency University of Calgary, 2024

Myositis Fellowship Johns Hopkins University, 2025

Biography

Dr. Eugene Krustev is a rheumatologist and clinician-scientist specializing in idiopathic inflammatory myopathies (IIM). His research focuses on biomarker discovery, disease mechanisms, and novel therapeutics in IIM. He completed his medical training at Memorial University, residency and rheumatology fellowship at the University of Calgary, and a clinical-research fellowship in myositis at Johns Hopkins University. 

Projects

Canadian Anti-MDA5 Syndrome Guidelines

We are currently developing the first Canadian clinical practice guidelines for the diagnosis and management of anti-MDA5 dermatomyositis, a rare but rapidly progressive autoimmune condition frequently complicated by high-mortality rates due to rapidly-progressive interstitial lung disease. This national initiative brings together Canadian experts from across all relevant subspecialties, alongside patient partners and trainees, to create evidence-based, consensus-driven recommendations tailored to the Canadian healthcare landscape. Our goal is to standardize care, improve early recognition and treatment pathways, and ultimately enhance outcomes for patients living with this severe form of myositis. This project would not be possible without the generous support of Myositis Canada.